KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 6037 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for ≥5 Years in the RESONATE-2 Study. PMID 36672456 · Cancers (Basel) · 2023-Jan-13 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 3 Figure · 5 Panel · risk visible
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein Vaccine. PMID 36523415 · medRxiv · 2023-Jan-13 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
General Anesthetics in CAncer REsection Surgery (GA-CARES) randomized multicenter trial of propofol vs volatile inhalational anesthesia: protocol description. PMID 36631831 · Perioper Med (Lond) · 2023-Jan-11 This is a protocol description for a Phase III randomized trial in oncologic surgery with a time-to-event primary endpoint (overall survival). However, it is a protocol without results, and the drug intervention (propofol vs. volatile anesthetic) is not a standard anticancer drug intervention as defined by the cohort criteria.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
OnabotulinumtoxinA: Still the Present for Chronic Migraine. PMID 36668879 · Toxins (Basel) · 2023-Jan-10 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial. PMID 36627711 · Trials · 2023-Jan-10 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Cancer Vaccines for Triple-Negative Breast Cancer: A Systematic Review. PMID 36679991 · Vaccines (Basel) · 2023-Jan-09 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. PMID 36331326 · Eur Heart J · 2023-Jan-07 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a). PMID 36674615 · Int J Mol Sci · 2023-Jan-06 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Adjuvant nivolumab versus placebo following radical surgery for high-risk muscle-invasive urothelial carcinoma: a subgroup analysis of Japanese patients enrolled in the phase 3 CheckMate 274 trial. PMID 36300304 · Jpn J Clin Oncol · 2023-Jan-06 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A Post Hoc Analysis of Efficacy Data on Sarecycline in Hispanics with Acne from Two Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trials. PMID 36671290 · Antibiotics (Basel) · 2023-Jan-04 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy of a bacterial 6-phytase supplemented beyond traditional dose levels on jejunal mucosa-associated microbiota, ileal nutrient digestibility, bone parameters, and intestinal health, and growth performance of nursery pigs. PMID 37115619 · J Anim Sci · 2023-Jan-03 仅见动物/临床前证据,不是人体临床试验。
H
仅历史库存 excludednon_human pending 0 Figure · 0 Panel · risk -
Assessment of Quality of Life Among Patients With Recurrent Clostridioides difficile Infection Treated with Investigational Oral Microbiome Therapeutic SER-109: Secondary Analysis of a Randomized Clinical Trial. PMID 36716031 · JAMA Netw Open · 2023-Jan-03 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine Trials. PMID 36689221 · JAMA Netw Open · 2023-Jan-03 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program. PMID 36600534 · Int J Gynecol Cancer · 2023-Jan-03 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized no_km 0 Figure · 0 Panel · risk not_applicable
A gated group sequential design for seamless Phase II/III trial with subpopulation selection. PMID 36597042 · BMC Med Res Methodol · 2023-Jan-03 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Remdesivir improves biomarkers associated with disease severity in COVID-19 patients treated in an outpatient setting. PMID 36596885 · Commun Med (Lond) · 2023-Jan-03 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
The efficacy and safety of anifrolumab in Japanese patients with systemic lupus erythematosus: TULIP-2 subanalysis. PMID 35134970 · Mod Rheumatol · 2023-Jan-03 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
AWOT and CWOT for genotype and genotype-by-treatment interaction joint analysis in pharmacogenetics GWAS. PMID 36661328 · Bioinformatics · 2023-Jan-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Influence of Vitamin D Supplementation on Growth, Body Composition, and Pubertal Development Among School-aged Children in an Area With a High Prevalence of Vitamin D Deficiency: A Randomized Clinical Trial. PMID 36441522 · JAMA Pediatr · 2023-Jan-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial. PMID 36394838 · JAMA Oncol · 2023-Jan-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 2 Figure · 3 Panel · risk visible
Efficacy and Safety of Vibegron for the Treatment of Overactive Bladder in Women: A Subgroup Analysis From the Double-Blind, Randomized, Controlled EMPOWUR Trial. PMID 36384907 · Urogynecology (Phila) · 2023-Jan-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Effect of brexanolone on depressive symptoms, anxiety, and insomnia in women with postpartum depression: Pooled analyses from 3 double-blind, randomized, placebo-controlled clinical trials in the HUMMINGBIRD clinical program. PMID 36191643 · J Affect Disord · 2023-Jan-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Morbidity, Mortality, and Pathologic Outcomes of Transanal Versus Laparoscopic Total Mesorectal Excision for Rectal Cancer Short-term Outcomes From a Multicenter Randomized Controlled Trial. PMID 35815886 · Ann Surg · 2023-Jan-01 干预为非药物单独策略,未满足药物干预要求。
H S B
严格 v3 独有 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Adverse Events in Patients Receiving Placebo in Phase III Trials of Biologics for Psoriasis: A Systematic Review and Meta-Analysis. PMID 39296949 · J Psoriasis Psoriatic Arthritis · 2023-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Evaluation of selenium source on nursery pig growth performance, serum and tissue selenium concentrations, and serum antioxidant status. PMID 37250345 · Transl Anim Sci · 2023-Jan 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Statistical assessment of the prognostic and the predictive value of biomarkers-A biomarker assessment framework with applications to traumatic brain injury biomarker studies. PMID 37009524 · Res Methods Med Health Sci · 2023-Jan 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Clinical Effect of Mirikizumab Treatment on Bowel Urgency in Patients with Moderately to Severely Active Ulcerative Colitis and the Clinical Relevance of Bowel Urgency Improvement for Disease Remission. PMID 36777368 · Crohns Colitis 360 · 2023-Jan 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy. PMID 36752726 · Future Oncol · 2023-Jan The record is a clinical trial protocol for a phase III randomized trial in oncology with a drug intervention, but it does not report results or explicitly identify a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS) with Kaplan-Meier or HR data. As a protocol, it does not meet the requirement for an original formal-result report.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Role of Adjuvant Radiotherapy in Gastric Cancer. PMID 36750999 · J Gastric Cancer · 2023-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Recent Advances in Sentinel Node Navigation Surgery for Early Gastric Cancer. PMID 36750996 · J Gastric Cancer · 2023-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Polatuzumab Vedotin for the Front-Line Treatment of Diffuse Large B-Cell Lymphoma: A New Standard of Care? PMID 36741209 · J Adv Pract Oncol · 2023-Jan 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized no_km 0 Figure · 0 Panel · risk not_applicable
A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiday highly emetogenic chemotherapy-induced nausea and vomiting (OFFER study). PMID 36712888 · EClinicalMedicine · 2023-Jan The trial is a randomized Phase III study in oncology with a drug intervention, but its primary efficacy endpoint is complete response rate (a categorical proportion), not a time-to-event endpoint such as OS, PFS, DFS, EFS, RFS, TTP, or a Kaplan-Meier/HR analysis. Therefore, it does not meet the cohort's requirement for a primary/key secondary time-to-event efficacy endpoint.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
An evaluation of the combination of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. PMID 36705941 · Expert Rev Neurother · 2023-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials. PMID 36639192 · Lupus Sci Med · 2023-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer. PMID 36634607 · J Natl Compr Canc Netw · 2023-Jan The record describes a biomarker analysis of AMH levels from the NeoALTTO trial, which is a randomized phase III study with drug interventions. However, the primary endpoint reported is the change in ovarian reserve (AMH levels), not a time-to-event efficacy endpoint like OS, PFS, DFS, EFS, RFS, TTP, or results presented via Kaplan-Meier/Hazard Ratio. Therefore, it does not meet the key inclusion criterion for a time-to-event efficacy endpoint.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Treatment of Patients with Multiple Sclerosis Transitioning Between Relapsing and Progressive Disease. PMID 36598730 · CNS Drugs · 2023-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
A series of two-sample non-parametric tests for quantile residual life time. PMID 36593432 · Lifetime Data Anal · 2023-Jan The article is a statistical methodology paper proposing new tests for quantile residual lifetime and applies them to a Phase III trial, but it is not an original clinical trial result report. It does not explicitly describe a drug intervention as the primary focus, and the main purpose is to introduce statistical methods rather than report trial efficacy. Therefore, it does not meet eligibility criteria for a drug intervention report.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A novel, fixed-dose calcipotriol and betamethasone dipropionate cream for the topical treatment of plaque psoriasis: Direct and indirect evidence from phase 3 trials discussed at the 30th EADV Congress 2021. PMID 36546465 · J Eur Acad Dermatol Venereol · 2023-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Veliparib with frontline chemotherapy and as maintenance in Japanese women with ovarian cancer: a subanalysis of efficacy, safety, and antiemetic use in the phase 3 VELIA trial. PMID 36534262 · Int J Clin Oncol · 2023-Jan 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 1 Figure · 2 Panel · risk visible
Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials. PMID 36528349 · Lancet Diabetes Endocrinol · 2023-Jan 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
The Role of Neoadjuvant Chemotherapy in Bladder Preservation Approaches in Muscle-Invasive Bladder Cancer. PMID 36517193 · Semin Radiat Oncol · 2023-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2). PMID 36509889 · Dermatol Ther (Heidelb) · 2023-Jan The study is a randomized Phase 3 trial of a drug (certolizumab pegol) with original results, but it is not in oncology (psoriasis) and the reported endpoints are quality-of-life outcomes, not time-to-event efficacy endpoints (e.g., OS, PFS, DFS, etc.) or Kaplan-Meier/HR analyses.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program. PMID 36478180 · Obesity (Silver Spring) · 2023-Jan 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effect of stereotactic body radiotherapy dose escalation plus pembrolizumab and trametinib versus stereotactic body radiotherapy dose escalation plus gemcitabine for locally recurrent pancreatic cancer after surgical resection on survival outcomes: A secondary analysis of an open-label, randomised, controlled, phase 2 trial. PMID 36471691 · EClinicalMedicine · 2023-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): Exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials. PMID 36467859 · EClinicalMedicine · 2023-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
The impact of population-based EGFR testing in non-squamous metastatic non-small cell lung cancer in Alberta, Canada. PMID 36463730 · Lung Cancer · 2023-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Objective response rate of placebo in randomized controlled trials of anticancer medicines. PMID 36444211 · EClinicalMedicine · 2023-Jan The record describes a pooled analysis of placebo response rates in multiple RCTs. It is not an original result report of a single randomized trial with a drug intervention and a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS).
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Safety and efficacy of propranolol for treatment of familial cerebral cavernous malformations (Treat_CCM): a randomised, open-label, blinded-endpoint, phase 2 pilot trial. PMID 36403580 · Lancet Neurol · 2023-Jan 未发现恶性肿瘤人群证据。
H S B
严格 v3 独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Daratumumab, Bortezomib, and Dexamethasone versus Bortezomib and Dexamethasone in Chinese Patients With Relapsed or Refractory Multiple Myeloma: Updated Analysis of LEPUS. PMID 36402700 · Clin Lymphoma Myeloma Leuk · 2023-Jan 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Corrigendum to 'Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep)' [European Journal of Cancer 169 (2022) 1-9]. PMID 36402625 · Eur J Cancer · 2023-Jan The record is a corrigendum to a study on health-related quality of life, not a time-to-event efficacy endpoint, and is not an original result report of the trial.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -